Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Yardley, Denise A., Lowell Hart, Anne Favret, Sibel Blau, Sami Diab, Donald Richards, Joseph Sparano, et al. “Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study..” Clin Breast Cancer 19, no. 4 (August 2019): 268-277.e1. https://doi.org/10.1016/j.clbc.2019.02.007.

PMID
31160171
Full Text

Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..” Breast Cancer Res Treat 176, no. 2 (July 2019): 321–28. https://doi.org/10.1007/s10549-019-05211-1.

PMID
31016641
Full Text

Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study..” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.

PMID
30635338
Full Text

Freedman, Rachel A., Rebecca S. Gelman, Carey K. Anders, Michelle E. Melisko, Heather A. Parsons, Anne M. Cropp, Kelly Silvestri, et al. “TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases..” J Clin Oncol 37, no. 13 (May 1, 2019): 1081–89. https://doi.org/10.1200/JCO.18.01511.

PMID
30860945
Full Text

Blackwell, Kimberly L., Khalil Zaman, Shukui Qin, Katherine H. R. Tkaczuk, Mario Campone, Daniel Hunt, Richard Bryce, Lori J. Goldstein, and Lori J. 202 Study Group. “Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study..” Clin Breast Cancer 19, no. 2 (April 2019): 97-104.e4. https://doi.org/10.1016/j.clbc.2018.12.011.

PMID
30655172
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Target Oncol 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.

PMID
30136059
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Target Oncol 14, no. 1 (February 2019). https://doi.org/10.1007/s11523-018-0614-x.

PMID
30535552
Full Text

Wu, Y., M. M. Amonkar, B. H. Sherrill, J. O’Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, and H. J. Burstein. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer..” Ann Oncol, January 9, 2019. https://doi.org/10.1093/annonc/mdy531.

PMID
30624581
Full Text

Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype..” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.

PMID
29615305
Full Text

Bardia, Aditya, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L. Blackwell, et al. “Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer..” Breast Cancer Res Treat 171, no. 1 (August 2018): 111–20. https://doi.org/10.1007/s10549-018-4813-z.

PMID
29744674
Full Text

Pages